New FDA-approved UV filter, DSM-Firmenich’s Parsol Shield enters the U.S. sunscreen market

DSM-Firmenich’s Parsol Shield brings bemotrizinol, the first FDA-approved new sunscreen active in more than 20 years, to U.S. sun-care formulas with an 18-month exclusivity window for the Swiss-Dutch group.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 2:58 PM ET. Details in the imprint.

Parsol Shield, DSM-Firmenich’s new UV filter based on bemotrizinol, is stepping into the U.S. market as the first freshly approved sunscreen active ingredient in more than two decades, giving formulators a long-awaited new tool for high-SPF, broad-spectrum protection. The ingredient has secured U.S. Food and Drug Administration (FDA) clearance for use in over-the-counter sunscreens, opening an 18-month period of market exclusivity for DSM-Firmenich as the sponsor of the approval process.

What Parsol Shield brings to U.S. sunscreen formulas

Bemotrizinol, the active behind Parsol Shield, has been used for years in Europe and parts of Asia, but until now U.S. brands were restricted to an older palette of UV filters that had not seen a new addition in over 20 years, limiting flexibility in balancing UVA and UVB coverage as well as texture and stability of high-factor products. According to DSM-Firmenich’s own announcement, Parsol Shield is a photostable, oil-soluble organic filter designed to deliver strong absorption across both UVA and UVB ranges while remaining compatible with a broad range of formulation types, from lightweight facial lotions to water-resistant beach sunscreens. The company states that the FDA approval covers bemotrizinol for over-the-counter sunscreen use in the United States and confirms an 18-month period during which DSM-Firmenich will hold exclusivity on the new filter in the U.S. market.

Industry reports note that U.S. sunscreen makers have been lobbying for years to gain access to newer-generation filters that are already standard elsewhere, arguing that the legacy U.S. filter set made it harder to combine strong UVA protection, photo-stability, and pleasant textures in a single product. Coverage of the FDA decision highlights that bemotrizinol is the first sunscreen ingredient to clear a streamlined review pathway created by Congress in 2020, marking it out as a test case for further additions to the U.S. filter toolbox and potentially reshaping how future UV actives are assessed. A recent industry article underscores that DSM-Firmenich will be the exclusive supplier of the new filter for 18 months in the United States because it sponsored the regulatory approval process.

The FDA itself has framed bemotrizinol’s approval as a milestone, noting in public communications that it represents the first new active sunscreen ingredient added to the U.S. over-the-counter monograph system in more than 20 years, after a long period in which several proposed filters stalled in regulatory limbo. Public-facing posts summarizing the decision emphasize that bemotrizinol can now be used as an active ingredient in U.S. sunscreen products, closing part of the gap between U.S. consumers and their counterparts in regions where multi-filter systems, including bemotrizinol, have been common for years. DSM-Firmenich has highlighted on its social channels that the FDA has formally added bemotrizinol to the list of permitted active ingredients for over-the-counter sunscreens.

For DSM-Firmenich’s Sun Protection business, Parsol Shield slots into an existing portfolio of UV filters that are widely used in global sunscreen brands, but the U.S.-specific approval gives the group a differentiated talking point in discussions with American personal-care companies looking to refresh their formulas. Management has previously framed sun protection as part of a broader “health and nutrition” narrative, and the new approval is likely to feature in that strategy, even if exact revenue contributions from individual UV filters are not broken out. Shares of dsm-firmenich AG (CH1216478797) last traded on Euronext Amsterdam at EUR 99.18 on 06/13/2026.

Parsol Shield key facts at a glance

• Product: Parsol Shield (bemotrizinol)
• Manufacturer: dsm-firmenich AG
• Category: Flagship UV filter for sun protection formulations
• Launch date: FDA approval for U.S. over-the-counter sunscreens announced June 2026
• MSRP / Price: Not disclosed; sold business-to-business as a specialty ingredient
• Availability: Supplied to sunscreen and personal-care manufacturers globally; now permitted for use in U.S. over-the-counter sunscreen products
• Target audience: Sunscreen and skincare brands seeking high-performance, broad-spectrum UV protection for U.S. and international markets
• Key differentiator / USP: First newly approved active sunscreen ingredient for U.S. over-the-counter products in more than 20 years, with an 18-month U.S. exclusivity period for DSM-Firmenich

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.